Dr. Archana Bharti Sonkar | Faculty | School of Pharmacy

Dr. Archana Bharti Sonkar
Assistant Professor

Dr. Archana Bharti Sonkar is a Pharmacology researcher with a Ph.D. from Babasaheb Bhimrao Ambedkar University, Lucknow, and over seven years of extensive research experience in cancer pharmacology and molecular therapeutics. Her research primarily focuses on understanding the molecular mechanisms underlying cancer progression, with particular emphasis on pathways such as interleukins, STAT3, and lactate transporters (MCT-1 and MCT-4), integrating in-vitro, in-vivo, and in-silico approaches. She has successfully led an ICMR-SRF funded research project investigating the antiproliferative effects of novel therapeutic compounds in lung carcinoma models, demonstrating significant expertise in preclinical cancer research using cell lines and animal models. She is an author and co-author in numerous research and review articles published in high-impact international journals, contributing to advancements in targeted therapy.

She has one granted patent in biomedical technology and another under process related to gene-silencing strategies in hypoxic cancer cells. She also has teaching experience in pharmacy education and has actively participated in national and international conferences, where she has presented her work through oral and poster presentations.

Dr. Sonkar’s research interests include cancer pharmacology, molecular and clinical pharmacology, antioxidant studies, targeted drug delivery, and RNA-based therapeutics. Her multidisciplinary expertise bridges experimental pharmacology with computational and translational approaches, aiming to develop effective and innovative therapeutic strategies for cancer management.

ORCID ID: https://orcid.org/0000-0002-2210-0438
Scopus ID: https://www.scopus.com/authid/detail.uri?authorId=57463875700
Vidwan ID: https://vidwan.inflibnet.ac.in/profile/697921
Google Scholar ID: https://scholar.google.com/citations?user=Q3GU9xwAAAAJ&hl=en

LIST OF RESEARCH PUBLICATION (Follow APA Style of referencing for writing)

• Yadav, S., Singh, J., Kumar, R., Sonkar, A. B., Kumar, A., Kumar, D., Shrivastava, N. K., Ansari, M. N., Saeedan, A. S., Aldossary, S. A., & Kaithwas, G. (2025). Anticancer efficacy of 2-hydroxy-4-methoxybenzoic acid through dual regulation of lactate transport via inhibition of MCT-1 and MCT-4. Advances in Cancer Biology-Metastasis, Article 100163.
• Shrivastava, N. K., Verma, P., Singh, G., Singh, J., Kumar, A., Yadav, S., Sonkar, A. B., Ansari, M. N., Saeedan, A. S., Akhter, Y., & Aldossary, S. A. (2025). Optimizing siRNA therapeutics targeting HIF-1α: Computational design, screening, and molecular dynamics simulation studies. Molecular Pharmaceutics, 22(6), 3179–3188.
• Yadav, S., Arman, M., Kumar, A., Sonkar, A. B., Shrivastava, N. K., Singh, J., Ansari, M. N., Aldossary, S. A., Saeedan, A. S., & Kaithwas, G. (2025). Antiproliferative effect of ketogenic diet on hormone-independent mammary gland carcinoma via harnessing glucose metabolism: In vitro and in vivo investigations. Journal of Genetic Engineering and Biotechnology, 23(2), Article 100480.
• Pandey, A. R., Kumar, A., Shrivastava, N. K., Singh, J., Yadav, S., Sonkar, A. B., Kumar, D., Kumar, R., Saeedan, A. S., Ansari, M. N., Aldossary, S. A., & Akhter, Y. (2025). Advancing siRNA therapeutics targeting MCT-4: A multifaceted approach integrating arithmetical designing, screening, and molecular dynamics validation. International Immunopharmacology, 147, Article 113980.
• Zaidi, A. K., Kumar, A., Kumar, R., Singh, J., Yadav, S., Sonkar, A. B., Kumar, D., Shrivastava, N. K., Ansari, M. N., Saeedan, A. S., & Kaithwas, G. (2025). Repurposing brucine as a chemopreventive agent in mammary gland carcinoma: Regulating lactate transport through MCT-4. Toxicology Reports, Article 101902.
• Singh, J., Yadav, S., Sonkar, A. B., Kumar, A., Shrivastava, N. K., Kumar, R., Kumar, D., Ansari, M. N., Saeedan, A. S., & Kaithwas, G. (2024). Design, synthesis, molecular dynamics, and gene silencing studies of novel therapeutic HIF-1α siRNAs in hypoxic cancer cells. International Journal of Biological Macromolecules, 282, Article 136943.
• Sonkar, A. B., Verma, A., Yadav, S., Kumar, R., Singh, J., Keshari, A. K., Rani, S., Kumar, A., Kumar, D., Shrivastava, N. K., et al. (2024). Antiproliferative effect of indeno[1,2-d]thiazolo[3,2-a]pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In silico, in vitro, and in vivo study. Cancer Cell International, 24, Article 219.
• Sonkar, A. B., Verma, A., Yadav, S., Singh, J., Kumar, R., Keshari, A. K., Kumar, A., Kumar, D., Shrivastava, N. K., Rani, S., et al. (2024). Antiproliferative, apoptotic, and anti-inflammatory potential of 5H-benzo[h]thiazolo[2,3-b]quinazoline analogues: Novel series of anticancer compounds. International Immunopharmacology, 137, Article 112496.
• Kumar, R., Kumar, A., Kumar, D., Yadav, S., Shrivastava, N. K., Singh, J., Sonkar, A. B., Verma, P., Arya, D. K., Kaithwas, G., et al. (2024). Harnessing the potential of omega-3 polyunsaturated fatty acid with nanotechnology for enhanced breast cancer therapy: A comprehensive investigation into ALA-based liposomal PTX delivery. Pharmaceutics, 16, Article 913.
• Deepak, P., Kumar, P., Pandey, P., Arya, D. K., Jaiswal, S., Kumar, A., Sonkar, A. B., Ali, D., Alarifi, S., Ramar, M., et al. (2023). Pentapeptide cRGDfK-surface engineered nanostructured lipid carriers as an efficient tool for targeted delivery of tyrosine kinase inhibitor for battling hepatocellular carcinoma. International Journal of Nanomedicine, 7021–7046.
• Sonkar, A. B., Kumar, P., Kumar, A., Gautam, A. K., Verma, A., Singh, A., Kumar, U., Kumar, D., Mahata, T., Bhattacharya, B., et al. (2023). Vinpocetine mitigates DMH-induced pre-neoplastic colon damage in rats through inhibition of pro-inflammatory cytokines. International Immunopharmacology, 119, Article 110236.
• Kumar, P., Kumar, M., Gautam, A. K., Sonkar, A. B., Verma, A., Singh, A., Nisha, R., Kumar, U., Kumar, D., Mahata, T., et al. (2022). Ameliorative effect of fluvoxamine against colon carcinogenesis via COX-2 blockade with oxidative and metabolic stress reduction at the cellular, molecular, and metabolic levels. BBA Advances, 2, Article 100046.
• Gautam, A. K., Kumar, V., Sonkar, A. B., Singh, A., Yadav, D., Rajan, N., Kumar, P., Singh, S., Saha, S., & Vijayakumar, M. R. (2025). Metabolites involvement in the growth and spread of liver cancer. Liver Research.
• Singh, A., Kumar, P., Sonkar, A. B., Gautam, A. K., Verma, A., Maity, B., Tiwari, H., Sahoo, N. G., Keshari, A. K., Yadav, S., et al. (2023). A comprehensive review on PCSK9 as a mechanistic target approach in cancer therapy. Mini Reviews in Medicinal Chemistry, 23, 24–32.
• Sonkar, A., Kumar, P., Gautam, A., Maity, B., & Saha, S. (2022). New scope of targeted therapies in lung carcinoma. Mini Reviews in Medicinal Chemistry, 22, 629–639.